ARIANA CAMPOS YANG
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
- Relative cost-effectiveness of using an extensively hydrolyzed casein formula in managing infants with cow's milk allergy in Brazil(2016) GUEST, Julian F.; YANG, Ariana C.; OBA, Jane; RODRIGUES, Maraci; CAETANO, Rosane; POLSTER, LilianObjective: To estimate the cost-effectiveness of three alternative dietetic strategies for cow's milk allergy in Brazil: 1) using an extensively hydrolyzed casein formula (eHCF; -Nutramigen) as a first-line formula, but switching to an amino acid formula (AAF) if infants remain symptomatic; 2) using an AAF as a first-line formula and then switching to an eHCF after 4 weeks once infants are symptom-free, but switching back to an AAF if infants become symptomatic; and 3) using an AAF as a first-line formula and keeping all infants on that formula. The analysis was conducted from the perspective of the Brazilian public health care system, Sistema Unico de Saude. Methods: Decision modeling was used to estimate the probability of immunoglobulin E (IgE)-mediated and non-IgE-mediated allergic infants developing tolerance to cow's milk by 12 months from starting a formula. The models also estimated the Sistema Unico de Saude cost (at 2013/2014 prices) of managing infants over 12 months after starting a formula, as well as the relative cost-effectiveness of each of the dietetic strategies. Results: The probability of developing tolerance to cow's milk by 12 months from starting a formula was higher among infants with either IgE-mediated or non-IgE-mediated allergy who were initially fed with an eHCF, compared with those who were initially fed with an AAF. The total health care cost of initially feeding an eHCF to cow's milk allergic infants was less than that of initially feeding both IgE-mediated and non-IgE-mediated infants with an AAF. Conclusion: Within the study's limitations, using an eHCF instead of an AAF for the first-line management of newly-diagnosed infants with cow's milk allergy affords a cost-effective use of publicly funded resources, since it improves the outcome for less cost.
- A concept for integrated care pathways for atopic dermatitis-A GA2LEN ADCARE initiative(2023) ZUBERBIER, Torsten; LATIFF, Amir Abdul; AGGELIDIS, Xenofon; AUGUSTIN, Matthias; BALAN, Radu-Gheorghe; BANGERT, Christine; BECK, Lisa; BIEBER, Thomas; BERNSTEIN, Jonathan A.; COLILLA, Marta Bertolin; BERARDI, Alejandro; SERRA-BALDRICH, Esther; SIEMENS, Kristina; SMITH, Cathrine; STAUBACH, Petra; STEVANOVIC, Katarina; SU-KUCUK, Ozlem; SUSSMAN, Gordon; TAVECCHIO, Simona; MITREVSKA, Natasa Teovska; THACI, Diamant; TOUBI, Elias; TRAIDL-HOFFMANN, Claudia; TREUDLER, Regina; VADASZ, Zahava; HOFMAN, Ingrid van; VENTURA, Maria Teresa; WANG, Zhao; WERFEL, Thomas; WOLLENBERG, Andreas; YANG, Ariana; YEW, Yik Weng; ZHAO, Zuotao; ZWIENER, Ricardo; WORM, Margitta; BEDBROOK, Anna; BINDSLEV-JENSEN, Carsten; BOUSQUET, Jean; BRUIN-WELLER, Marjolein de; BRUSCKY, Dayanne; BUYUKTIRYAKI, Betul; CANONICA, Giorgio Walter; CASTRO, Carla; CHANTURIDZE, Natia; CHONG-NETO, Herberto Jose; CHU, Chia-Yu; CHULAROJANAMONTRI, Leena; CORK, Michael; CRIADO, Roberta F. J.; BARREDO, Laia Curto; CUSTOVIC, Adnan; DARSOW, Ulf; EMURLAI, Arben; PABLO, Ana de; GIACCO, Stefano Del; GIROLOMONI, Giampiero; JOVANOVA, Tanja Deleva; DELEURAN, Mette; DOULADIRIS, Nikolaos; DUARTE, Bruno; DUBAKIENE, Ruta; ELLER, Esben; ENGEL-YEGER, Batya; ENSINA, Luis Felipe; FILHO, Nelson Rosario; FLOHR, Carsten; FOMINA, Daria; FRANCUZIK, Wojciech; GALIMBERTI, Maria Laura; GIMENEZ-ARNAU, Ana M.; GODSE, Kiran; MORTZ, Charlotte Gotthard; GOTUA, Maia; HIDE, Michihiro; HOETZENECKER, Wolfram; HUNZELMANN, Nicolas; IRVINE, Alan; JACK, Carolyn; KANAVAROU, Ioanna; KATOH, Norito; KINACIYAN, Tamar; KOCATUERK, Emek; KULTHANAN, Kanokvalai; LAPEERE, Hilde; LAU, Susanne; NASTRI, Mariana Machado Forti; MAKRIS, Michael; MANSOUR, Eli; MARSLAND, Alexander; FELIX, Mara Morelo Rocha; CASTRO, Ana Paula Moschione; NETTIS, Eustachio; NICOLAS, J. F.; NOSBAUM, Audrey; ODEMYR, Mikaela; PAPAPOSTOLOU, Niki; PARISI, Claudio A. S.; PAUDEL, Sushil; PETER, Jonny; POKHAREL, Prakash; PUIG, Luis; QUINT, Tamara; RAMON, German Dario; REGATEIRO, Frederico; RICCI, Giampaolo; ROSARIO, Cristine; SACKESEN, Cansin; SCHMID-GRENDELMEIER, PeterIntroduction: The integrated care pathways for atopic dermatitis (AD-ICPs) aim to bridge the gap between existing AD treatment evidence-based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co-ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems.Methods: The GA(2)LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD-ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL(2)EN ADCARE centres.Results: The AD-ICPs outline the diagnostic procedures, possible co-morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD.Conclusion: The AD-ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.